The TMR procedure seems to be a VERY effective way to treat late stages of heart deases. The cost of the procedure is extreamly low and once it is common place, the insurance industry will really push for it as a less evasive operation (cost less) IMO.
PLC is the leader at this time. They have done that last I heard 6,000+ procedures. They are selling the machines overseas and should be receiving FDA approval very soon (let keep those fingers crossed - I have some stock in them).
Reports are that this is a $100B industry and there are only a few companies even attempting to enter. What I like about ESTI is their new process by using the catheter-based version for use by cardiologists in a procedure called Percutaneous Transluminal Myocardial Revascularization, or ``PTMR.''
If they follow PLC, after filing the PMA, it may take up to a year to get approval from the FDA. In the meantime - they are loosing money.
SUNNYVALE, Calif., July 10 /PRNewswire/ -- Eclipse Surgical Technologies, Inc. (Nasdaq:ESTI) today announced results for the quarter ended June 30, 1997. Net revenues for the quarter ended June 30, 1997 were $1.25 million, compared to $2.21 million in the second quarter of 1996. Net loss for the second quarter was $4.64 million, or $0.28 per share, compared to $730,000 or $0.05 per share in the second
quarter of 1996. Cash and marketable securities as of June 30, 1997 totalled $43.7 million, with virtually no outstanding debt.
All of these companies are going through this. As long as they can cover the cost of developing the product, they will succeed when the FDA gives their blessing.
John |
